CIT expands US presence

Appoints vice-president of business development North America

CIT, a French non-clinical CRO, has opened a US subsidiary, CITox, in Boston, Massachusetts, to spearhead the planned expansion of its US activities.

The company has appointed Bernard Galat as vice-president, business development, North America, who will be based in the Boston office.

The US represents 15% of CIT’s current sales; the aim is to increase this to 30% in three to five years.

Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron, Parexel and Carestat.

‘This is an exciting time to be joining CIT as we expand the availability of our services in monoclonal antibody therapies, tissue cross-reactivity, functional genomics, safety pharmacology and carcinogenicity, including transgenic models,’ he said.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Subscribe now